Four-drug combination chemotherapy in advanced lung cancer: Methotrexate, doxorubicin, cyclophosphamide and CCNU

David M. Milstein, E. Robinson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

One-hundred-twenty patients with advanced lung cancer were treated by the MACC (methotrexate, doxorubicin (Adriamycin), cyclophosphamide and CCNU) regimen. Ninety-eight patients were evaluated. Objective complete response occurred in one case for 27+ months. Partial response was observed in 20 patients lasting for a median of 4.7 months. The overall objective response rate was 21% and the median duration of response was 5.5 months. Stable disease was noted in 44 patients with a median time to progression of 4.7 months from the start of treatment. Tumor progression occurred in 33 cases. There was a significant prolongation of median acturarial survival of responders (11.2 months) vs. stable disease (6.2 months) or vs. non-responders (3.8 months, P<0.05). The median actuarial survival for the whole group was 7.3 months. Bone marrow toxicity including thrombocytopenia (<100,000 cells/mm3) occurred in 16 patients and leukopenia (<3000 cells/mm3) in 24 patients. Forty-seven patients had no hematologic toxicity. Other adverse reactions were nausea and vomiting (50%), stomatitis (16%), alopecia (5%), cardiotoxicity (1%) and fever during leukopenia (1%).

Original languageEnglish (US)
Pages (from-to)2358-2363
Number of pages6
JournalCancer
Volume48
Issue number11
StatePublished - 1981
Externally publishedYes

Fingerprint

Lomustine
Drug Combinations
Combination Drug Therapy
Methotrexate
Doxorubicin
Cyclophosphamide
Lung Neoplasms
Leukopenia
Stomatitis
Survival
Alopecia
Thrombocytopenia
Nausea
Vomiting
Fever
Bone Marrow

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Four-drug combination chemotherapy in advanced lung cancer : Methotrexate, doxorubicin, cyclophosphamide and CCNU. / Milstein, David M.; Robinson, E.

In: Cancer, Vol. 48, No. 11, 1981, p. 2358-2363.

Research output: Contribution to journalArticle

Milstein, David M. ; Robinson, E. / Four-drug combination chemotherapy in advanced lung cancer : Methotrexate, doxorubicin, cyclophosphamide and CCNU. In: Cancer. 1981 ; Vol. 48, No. 11. pp. 2358-2363.
@article{0bf466aae0d140a3a629aa9883c57187,
title = "Four-drug combination chemotherapy in advanced lung cancer: Methotrexate, doxorubicin, cyclophosphamide and CCNU",
abstract = "One-hundred-twenty patients with advanced lung cancer were treated by the MACC (methotrexate, doxorubicin (Adriamycin), cyclophosphamide and CCNU) regimen. Ninety-eight patients were evaluated. Objective complete response occurred in one case for 27+ months. Partial response was observed in 20 patients lasting for a median of 4.7 months. The overall objective response rate was 21{\%} and the median duration of response was 5.5 months. Stable disease was noted in 44 patients with a median time to progression of 4.7 months from the start of treatment. Tumor progression occurred in 33 cases. There was a significant prolongation of median acturarial survival of responders (11.2 months) vs. stable disease (6.2 months) or vs. non-responders (3.8 months, P<0.05). The median actuarial survival for the whole group was 7.3 months. Bone marrow toxicity including thrombocytopenia (<100,000 cells/mm3) occurred in 16 patients and leukopenia (<3000 cells/mm3) in 24 patients. Forty-seven patients had no hematologic toxicity. Other adverse reactions were nausea and vomiting (50{\%}), stomatitis (16{\%}), alopecia (5{\%}), cardiotoxicity (1{\%}) and fever during leukopenia (1{\%}).",
author = "Milstein, {David M.} and E. Robinson",
year = "1981",
language = "English (US)",
volume = "48",
pages = "2358--2363",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Four-drug combination chemotherapy in advanced lung cancer

T2 - Methotrexate, doxorubicin, cyclophosphamide and CCNU

AU - Milstein, David M.

AU - Robinson, E.

PY - 1981

Y1 - 1981

N2 - One-hundred-twenty patients with advanced lung cancer were treated by the MACC (methotrexate, doxorubicin (Adriamycin), cyclophosphamide and CCNU) regimen. Ninety-eight patients were evaluated. Objective complete response occurred in one case for 27+ months. Partial response was observed in 20 patients lasting for a median of 4.7 months. The overall objective response rate was 21% and the median duration of response was 5.5 months. Stable disease was noted in 44 patients with a median time to progression of 4.7 months from the start of treatment. Tumor progression occurred in 33 cases. There was a significant prolongation of median acturarial survival of responders (11.2 months) vs. stable disease (6.2 months) or vs. non-responders (3.8 months, P<0.05). The median actuarial survival for the whole group was 7.3 months. Bone marrow toxicity including thrombocytopenia (<100,000 cells/mm3) occurred in 16 patients and leukopenia (<3000 cells/mm3) in 24 patients. Forty-seven patients had no hematologic toxicity. Other adverse reactions were nausea and vomiting (50%), stomatitis (16%), alopecia (5%), cardiotoxicity (1%) and fever during leukopenia (1%).

AB - One-hundred-twenty patients with advanced lung cancer were treated by the MACC (methotrexate, doxorubicin (Adriamycin), cyclophosphamide and CCNU) regimen. Ninety-eight patients were evaluated. Objective complete response occurred in one case for 27+ months. Partial response was observed in 20 patients lasting for a median of 4.7 months. The overall objective response rate was 21% and the median duration of response was 5.5 months. Stable disease was noted in 44 patients with a median time to progression of 4.7 months from the start of treatment. Tumor progression occurred in 33 cases. There was a significant prolongation of median acturarial survival of responders (11.2 months) vs. stable disease (6.2 months) or vs. non-responders (3.8 months, P<0.05). The median actuarial survival for the whole group was 7.3 months. Bone marrow toxicity including thrombocytopenia (<100,000 cells/mm3) occurred in 16 patients and leukopenia (<3000 cells/mm3) in 24 patients. Forty-seven patients had no hematologic toxicity. Other adverse reactions were nausea and vomiting (50%), stomatitis (16%), alopecia (5%), cardiotoxicity (1%) and fever during leukopenia (1%).

UR - http://www.scopus.com/inward/record.url?scp=0019779936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019779936&partnerID=8YFLogxK

M3 - Article

C2 - 7028245

AN - SCOPUS:0019779936

VL - 48

SP - 2358

EP - 2363

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -